CD36 and neoplasm: Xiying Yu used sorafenib as a tumor promoter to establish an NMBzA-induced rat ESCC carcinogenesis model, the multi-omic result of their research indicated that NMBzA-induced rat ESCCs are accompanied by progressive hyperactivations of the FAT-Hippo-YAP1 axis, and inhibitors of YAP1 block the growth of rat ESCCs [293].